Digital Prescription: Dana-Farber Cancer Institute on Multiple Myeloma

Doctors are learning how to diagnose and treat smoldering multiple myeloma, which precedes active myeloma. They want to prevent progression.

If you have smoldering myeloma, doctors will say to 'watch and wait.' Dr. Ghobrial thinks that doesn't make sense, and tells us how she's changing that.

Learn about MGUS, a disease present in the body before multiple myeloma, and the risk of it progressing to active myeloma.

Researchers are currently developing a cancer vaccine to prevent smoldering myeloma and MGUS from progressing into active myeloma.

Hope--although we don't use this word lightly, patients with multiple myeloma should truly be hopeful. Dr. Richardson tells us about progress in treatment.

Multiple myeloma patients will be categorized into one of two groups: standard risk or high risk. This distinction determines their treatment course.

Just like the military deploying army, navy, coast guard, and marines to defend the country, oncologists deploy a combination of drugs to fight off myeloma

The majority of patients respond very well to stem-cell transplants, but there can be serious short term and long term side effects.

Maintenance therapy is essential for both standard-risk and high-risk patients, as its been proven to extend life significantly.

Long term use of Revlimid (lenalidomide) can extend your life by years, keeping the cancer at bay using your immune system.

When myeloma relapses, it comes back stronger than ever. That's why oncologists are using a combination therapy of four drugs to tackle it

Treatment itself can actually be the cause of why myeloma comes back stronger than ever. Learn about the signs that your myeloma has relapsed.

We're here to tell you why modern medicine is changing the game, and what your options are to tackle the disease.

Selinexor, a new class of drugs, is showing promise as a way to treat people with multiple myeloma who don't seem to be responding to other treatment.